204 results about "Herpes simplex virus" patented technology

The invention discloses a reagent and a method for detecting berberine-resistant viruses. The reagent provided by the invention comprises an antibody or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR1-3 and / or a light chain complementarity determining region LCDR1-3, the heavy chain complementarity determining region HCDR1-3 has a sequence as shown in SEQ ID NO.5-7, and the light chain complementarity determining region LCDR1-3 has a sequence as shown in SEQ ID NO.8-10. The reagent can be used for detecting the berberine-resistant herpes simplex virus type 1, so that the treatment effect can be evaluated in advance before berberine is applied for treatment.

The invention provides a novel three-antigen HSV-2 adjuvant subunit vaccine as well as a preparation method and application thereof. The vaccine comprises herpes simplex virus recombinant protein and a composite adjuvant, the herpes simplex virus recombinant protein comprises extracellular domains of three proteins, namely HSV-2gE, gD and gC, wherein the amino acid sequences of the extracellular domains of the HSV-2gE, the gD and the gC are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; and the composite adjuvant is composed of CpG oligodeoxynucleotide and QS-21. Experiments prove that by adding the composite adjuvant composed of CpG oligodeoxynucleotide and QS-21, the immunogenicity, in-vivo protectiveness, virus removal and other immune functions of the HSV-2 subunit vaccine can be remarkably improved; meanwhile, the vaccine is a cross immune protection vaccine of an HSV-2 virus strain and an HSV-1 virus strain.

The invention provides a kit and a method for simultaneously detecting 11 pathogens of a urogenital system and application, and belongs to the field of molecular biology. The primer group is used for detecting urogenital tract pathogens, and the urogenital tract pathogens comprise ureaplasma urealyticum (UU), chlamydia trachomatis (CT), mycoplasma genitalium (MG), ureaplasma parvum (UP), mycoplasma hominis (MH), adenovirus (ADV), trichomonas vaginalis (TV), herpes simplex virus type I (HSV-I), herpes simplex virus type II (HSV-II), haemophilus influenzae (HI) and neisseria gonorrhoeae (NG). The primer group is used for multi-joint detection of non-gonococcal urethritis related pathogens, has high specificity and sensitivity, is adaptive to non-invasive urine specimens, and supports home self-sampling. The kit is used for clinical diagnosis and can quickly judge pathogen types. Precise medication is performed based on a detection result, the healing time of a patient is shortened, the burden of a doctor is relieved, and meanwhile the pathogen transmission risk is reduced.

The present disclosure provides a polyribonucleotide encoding a polypeptide that comprises a viral antigen from Herpes Simplex Virus-2 (HSV-2); for example, the viral antigen comprises the ectodomain of HSV-2 glycoprotein B. The polyribonucleotide can be formulated as an RNA composition useful for inducing anti-HSV immune responses in a subject.

The invention discloses pyridone endoperoxide with antibacterial and antiviral activity and application thereof, and belongs to the fields of organic compound synthesis and medical technology, food engineering and the like. The invention proves that the series of endoperoxides can effectively kill pathogenic bacteria, fungi and viruses, including propionibacterium acnes, escherichia coli, staphylococcus aureus, candida albicans, human papilloma viruses, herpes simplex viruses and the like. The internal peroxide designed by the invention has the capability of treating skin diseases, is expected to be developed into a first-line medicine for treating skin diseases caused by pathogen invasion, and mainly relates to bacterial skin diseases, fungal skin diseases and viral skin diseases caused by pathogen infection. Meanwhile, the series of endoperoxides can be used for treating oral infection, periodontitis, infection of shoulder and other joint operations, and bacterial infection such as pressure sores. In addition, the peroxides in the series can also be used in the fields of food preservation, disinfectant preparation and the like.

The invention discloses an HSV-1 replication-deficient recombinant virus vector and an application of the HSV-1 replication-deficient recombinant virus vector. Specifically, the method comprises the following steps: performing gene editing on a specific genome segment in an HSV-1 genome to obtain an HSV-1 replication-defective recombinant virus vector; wherein compared with the existing HSV-1 replication-deficient recombinant virus vector, the HSV-1 replication-deficient recombinant virus vector can express an exogenous gene more efficiently, and the HSV-1 replication-deficient recombinant virus vector, as an excellent delivery vector, can effectively deliver the exogenous gene into the body of a subject to achieve a treatment effect.

The invention discloses a novel helper plasmid for producing a recombinant adeno-associated virus as well as a construction method and application of the novel helper plasmid. The novel helper plasmid is constructed by inserting a UL12 element of an I-type herpes simplex virus HSV-1 and an NS2 element of a human bola virus HBoV into a basic pHelper plasmid, the constructed novel helper plasmid UL12-NS2-pHelper can remarkably improve the titer of rAAV produced by HEK293 cells, the proportion of solid rAAV is increased, immunoreaction and toxicity caused by empty capsid can be reduced, and the helper plasmid can be used for preparing the rAAV. The treatment dosage is reduced, and the curative effect and safety are improved.

The present invention discloses a biomarker for predicting the efficacy of oncolytic virus in treating malignant tumors and its application. The biomarker includes SH3BP2, the oncolytic virus is oncolytic herpes simplex virus, and the malignant tumor is glioma. Before treating malignant glioma with oncolytic virus, the expression level of SH3BP2 in tumor tissues before treatment is detected to predict the therapeutic effect of oncolytic virus on malignant glioma.

The invention relates to the field of medicinal chemistry, and particularly discloses purine compounds as well as a preparation method and application thereof. The purine compound provided by the invention is a compound as shown in a formula (I) or pharmaceutically acceptable salt thereof: # imgabs0 #. The purine compound disclosed by the invention is designed based on a novel purine skeleton structure, and the anti-herpes simplex virus type 1 (HSV-1) activity of the purine compound is verified through an in-vitro antiviral experiment. Experimental data show that the HSV-1 median inhibitory concentration (EC50) of the series of compounds to HSV-1 is obviously superior to that of a clinical first-line drug acyclovir, and the series of compounds show better virus inhibition efficiency on the premise of keeping a similar selectivity index (SI = CC50 / EC50). The technical scheme breaks through the molecular framework limitation of the existing anti-HSV-1 drugs (such as acyclovir, famciclovir and the like), and has good clinical transformation value.

The invention belongs to the field of medicines, and particularly relates to application of fructose-1, 6-diphosphate in preparation of a medicine for preventing and treating herpes simplex virus type 1 infection. The fructose-1, 6-diphosphate (FBP) can be used for inhibiting replication of RNA (Ribonucleic Acid) and DNA (Deoxyribose Nucleic Acid) viruses in vitro and in vivo. Experiments show that the inhibition effect does not depend on I-type interferon-mediated innate immunity to a great extent, but occurs through HMGB1 (High Mobility Group Box 1). After virus infection, FBP reduces the protein level of HMGB1 by promoting lysosome degradation of HMGB1. In addition, the FBP can directly inhibit the combination of the HMGB1 and the viral genome, so that the virus replication is inhibited. The key effect of FBP in inhibition of virus replication is highlighted through research, and a potential target spot for controlling virus infection is provided.

The present invention relates to an immunogenic composition and a related vaccine composition comprising one or more nucleic acid(s) encoding structural proteins of Herpes Simplex Virus 2 (HSV-2) or immunogenic fragments thereof. The vaccine composition may be used for the treatment and / or prevention of HSV-2 infection and is particulary beneficial for the immunological control of periodic reactivation of the virus in infected patients.

Provided are a promoter of a gene specifically expressed in fetal trophoblast cells and a gene specifically expressed in fetal nucleated red blood cell-specific expression gene, as well as a recombinant herpes simplex virus type I obtained by replacing the wild type promoter of the genomic ICP of the recombinant herpes simplex virus type I with the aforesaid promoter and preparation and use thereof. Also provided are a diagnostic kit for prenatal screening and use thereof, as well as a method for isolating fetal cells from a maternal blood sample in pregnancy.

The invention relates to the technical field of pathogen detection, in particular to a primer and a probe for detecting treponema pallidum, a herpes simplex virus 1 and a herpes simplex virus 2 through single-tube multiplex fluorescent PCR, and further relates to a fluorescent PCR kit comprising the primer and the probe and application of the fluorescent PCR kit. The primer comprises specific sequences which respectively aim at the treponema pallidum, the herpes simplex virus 1 and the herpes simplex virus 2 and are not subjected to cross reaction, and the specific sequences of the primer and the probe are as shown in SEQ ID NO: 1-SEQ ID NO: 9. The kit can be used for simultaneously detecting various sexually transmitted pathogens such as treponema pallidum, herpes simplex virus 1 and herpes simplex virus 2, and the technical effects of high sensitivity and accuracy, strong specificity and simplicity and convenience in operation are well realized.

An HSV vector comprising an expression cassette for one or more of IL12, IL15, and hIL15Receptor alpha subunit is provided.

The invention relates to the field of biology, in particular to a herpes simplex virus strain and application thereof as well as a progeny culture and an attenuated modified variant of the herpes simplex virus strain. The present application also relates to a pharmaceutical composition comprising said herpes simplex virus and to the therapeutic use of said pharmaceutical composition.

A method of treating spasm in a subject is provided. The method comprises directly administering a herpes simplex virus type 1 (HSV-1) vector carrying a glutamate decarboxylase (GAD) gene (preferably GAD67) to one or more epithelial regions of the subject.

Disclosed herein are high transducing replication defective herpes simplex virus (HSV) vectors of McKrae strain.

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

The invention provides a recombinant herpes simplex virus and a herpes simplex virus modification method. The herpes simplex virus modification method comprises the step of replacing an ICP4 protein coding gene in a herpes simplex virus genome containing an infected cell protein 4 (ICP4) gene with an hTERTp-fluorescent protein expression cassette. The expression cassette comprises an hTERTp promoter and a fluorescent protein coding sequence controlled by the hTERTp promoter, and the transcription direction is opposite to that of an ICP4 promoter in a genome. The hTERTp-fluorescent protein expression cassette in the recombinant virus obtained by the method disclosed by the invention can be normally expressed in response to telomerase activity. Therefore, the recombinant virus is capable of expressing a fluorescent protein, such as mBaoJin, in a cell having human telomerase activity. Cells infected by the virus can be identified through fluorescence signals, and the higher the telomerase activity is, the stronger the fluorescence intensity is. The virus has wide application value in research of tumor action mechanisms and stem cell action mechanisms, health assessment, screening of tumor drugs, research and development of diagnostic reagents and establishment of animal models.

Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer / promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).

Provided herein is a herpes simplex virus 1 (HSV-1) recombinant virus, comprising one or more therapeutic payload sequences, wherein the genome comprises at least one alteration in each of a gene encoding infected cell polypeptides (ICP)0, a gene encoding ICP4, a gene encoding ICP22, a gene encoding ICP27 and a gene encoding ICP47, wherein the genome does not encode a functional ICP0, ICP4, ICP22, ICP27 and ICP47 protein, and wherein the genome comprises internal inverted repeat (joint) regions. Methods for using the same are also provided.

The present invention relates to a liquid composition characterized in that it comprises: a live attenuated herpes simplex virus 1 (HSV-1); 17.5 mg / mL to 22.5 mg / mL of recombinant human serum albumin (rHSA); less than 5 mg / mL of sucrose; 26 mg / mL to 32 mg / mL of sorbitol; 13.5 mg / mL to 16 mg / mL of potassium phosphate and 3 mg / mL to 7 mg / mL of sodium chloride, wherein the liquid composition comprises no more than 0.01 mM of any of lactose, gelatin, antibiotic and free amino acids.

The present invention belongs to a new use of verrucine, and particularly relates to the use of verrucine and verrucine extract in the preparation of antiviral drugs. Verrucine has an inhibitory effect on porcine delta coronavirus, porcine epidemic diarrhea virus, pseudorabies virus, herpes simplex virus, influenza virus or African swine fever virus. The verrucine extract and verrucine of the present invention are very effective in antiviral treatment. The verrucine extract and verrucine of the present invention are very effective in broad-spectrum antiviral treatment, are safe, have few toxic and side effects, have low drug residues and are pollution-free.

The invention belongs to the field of biological medicine, and discloses an artificially synthesized polypeptide and application thereof in resisting herpes simplex virus type I. The polypeptide provided by the invention has a very good antiviral effect and slight toxic and side effects, and can resist brain and systemic infection caused by herpes simplex virus type I. The antiviral mechanism of the polypeptide is clear, and favorable guarantee is provided for application and optimization of subsequent polypeptide inhibitors.

The invention discloses a function and an application of a fish LIM and SH3 structural domain protein 1 (LASP1) gene in fish antiviral immune regulation, and particularly discloses a molecular mechanism and an application value of the LASP1 as an immune negative regulation factor in carassius auratus herpesvirus (CaHV) infection. Experiments prove that fish LASP1 has the function of remarkably inhibiting immune regulation generated by host interferon and can promote CaHV proliferation for the first time, and knock-down of the gene can effectively enhance host antiviral response and inhibit CaHV infection. Therefore, the lasp1 gene can be used as a new target for preventing and treating CaHV infection, is used for preparing a preparation for preventing or treating CaHV infection, or is used for gene editing of a cell model for preventing CaHV infection or a new crucian carp variety.

Provided herein are Vero cell lines that stably express Herpes Simplex Virus (HSV) ICP0 protein. These cells have the same morphology of Vero cells, exhibit stable expression of HSV ICP0 protein, and also efficiently complement replication of HSV ICP0 deficient virus for greater than 20, 30, or even 40 cell passages.

The technical problem is to develop a novel armed oncolytic herpes simplex virus (HSV) with G47 delta as a skeleton. Provided is a pharmaceutical composition containing an IL-12 expression-type genetically recombinant herpes simplex virus (HSV) that has a gene encoding a fusion polypeptide in which a 35 kDa light chain (p35) and a 40 kDa heavy chain (p40) of interleukin 12 (IL-12) are linked by two or more elastin motifs, and that has the following characteristics (a) to (c). (a) the ICP6 gene is deleted or inactivated; (b) deletion or inactivation of the gamma34.5 gene; and (c) the alpha 47 gene is deleted or inactivated.

Disclosed is a replication incompetent HSV-1 viral vaccine comprising a modified genome of HSV-1 and at least one antigen. The modification comprises a deletion of internal repeats, an inactivating mutation in ICP47 and an inactivating mutation in the other copy of ICP4. A first antigen of the at least one antigen is driven by a promoter of an immediate early gene, such as ICP4. In a specific example, the HSV-1 viral vaccine expresses antigens from SARS-Cov, SARS-Cov-2 and variants thereof and is used for inducing immune responses against sarbecoviruses in a subject to which the vaccine is administered.

Provided herein are non-natural herpes simplex virus (“HSV”) vectors and one or more polynucleotides encoding IL-21 or a biologically active fragment of IL-21 for use in the treatment of cancer.

The invention discloses application of isodehydroicaritin in preparation of anti-I-type herpes simplex virus drugs, and particularly, the isodehydroicaritin inhibits proliferation of I-type herpes simplex virus, and the isodehydroicaritin is expressed as inhibiting total protein expression of the I-type herpes simplex virus, reducing the number of I-type herpes simplex virus particles and reducing the titer of the I-type herpes simplex virus. The application of the isodehydroicaritin in the medical field is expanded, it is disclosed for the first time that the isodehydroicaritin can inhibit reproduction of the I-type herpes simplex virus, and the isodehydroicaritin can be used for preparing the medicine for preventing and treating the herpes simplex virus.